Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
View Patent ↗This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins, having the amino acid sequences set forth in any of FIG. 18 A, 18 B- 1 - 18 B- 3, 18 C- 1 - 18 C- 2, 18 D- 1 - 18 D- 2 or 18 E- 1 - 18 E- 2 . Oligonucleotides of the isolated nucleic acid molecules are provided. Antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins are also provided, as are pharmaceutical compositions comprising such antibodies or oligonucleotides. Methods for detecting a B cell malignancy in a sample from a subject; diagnosing B cell malignancy in a sample from a subject; detecting human IRTA protein in a sample; and treating a subject having a B cell cancer are also provided.
1. A purified antibody directed to a human IRTA3 protein, wherein the amino acid sequence of the human IRTA3 protein is set forth in SEQ ID NO:5.
2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.
3. The antibody of claim 2 , wherein the monoclonal antibody is a murine monoclonal antibody or a humanized monoclonal antibody.
4. The antibody of claim 1 , wherein the antibody is conjugated to a therapeutic agent selected from the group consisting of a radioisotope, a toxin, a toxoid, or a chemotherapeutic agent.
5. A composition comprising an amount of the antibody of claim 1 which binds to a human IRTA protein effective to bind to cancer cells expressing IRTA3 protein so as to prevent growth of the cancer cells, and a pharmaceutically acceptable carrier, wherein the amino acid sequence of the human IRTA3 protein is set forth in SEQ ID NO:5.
6. The composition of claim 5 , wherein the cancer cells are selected from group consisting of B cell lymphoma cells, mantle cell lymphoma cells, multiple myeloma cells, Burkitt's lymphoma cells, marginal zone lymphoma cells, diffuse large cell lymphoma cells, and follicular lymphoma cells.
7. The composition of claim 6 , Wherein the B cell lymphoma cells are Mucosa-Associated Lymphoid Tissue (MALT) B cell lymphoma cells.
8. The composition of claim 6 , wherein the B cell lymphoma cells are non-Hodgkin's lymphoma cells.
9. The composition of claim 1 , wherein the antibody is a monoclonal antibody.
10. The composition of claim 9 , wherein the antibody is a humanized antibody.
11. An antibody of claim 1 , which specifically binds to the extracellular domain of the human IRTA3 protein expressed on the surface of a cancer cell.
12. The antibody of claim 11 , wherein the antibody is a monoclonal antibody.
13. The antibody of claim 12 , wherein the antibody is a humanized antibody.
14. The antibody of claim 11 , wherein the antibody is conjugated to a therapeutic agent selected from the group consisting of a radioisotope, a toxin, a toxoid, or a chemotherapeutic agent.
15. The antibody of claim 14 , wherein the antibody is a monoclonal antibody.
16. The antibody of claim 14 , wherein the antibody is a humanized antibody.
17. A composition comprising a pharmaceutically acceptable carrier and an antibody which binds to a human IRTA3 protein, wherein the antibody is conjugated to a therapeutic agent selected from the group consisting of a radioisotope, a toxin, a toxoid, or a chemotherapeutic agent, wherein the amino acid sequence of the human IRTA3 protein is set forth in SEQ ID NO:5 and wherein the antibody conjugated to the therapeutic agent is present in an amount effective to bind cancer cells expressing IRTA3 protein so as to prevent growth of the cancer cells.